Casey Ruoying Cai

Dr. Casey Ruoying Cai

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ECEric J. Chow
Eric J. Chow
YCYan Chen
Yan Chen
GAGregory T. Armstrong
Gregory T. Armstrong
LBLaura‐Mae Baldwin
Laura‐Mae Baldwin
CCCasey Ruoying Cai
Casey Ruoying Cai
YYYutaka Yasui
Yutaka Yasui
Background: Determine the prevalence and predictors associated with underdiagnosis and undertreatment of modifiable cardiovascular disease (CVD) risk factors (hypertension, dyslipidemia, glucose intolerance/diabetes) among adult survivors of childhood cancer at high risk of premature CVD. Methods and Results: This was a cross‐sectional study of adult‐aged survivors of childhood cancer treated with anthracyclines or chest radiotherapy, recruited across 9 US metropolitan regions. Survivors completed questionnaires and in‐home clinical assessments. The comparator group was a matched sample from the National Health and Nutrition Examination Survey. Multivariable logistic regression estimated the risk (odds ratios) of CVD risk factor underdiagnosis and undertreatment among survivors compared with the National Health and Nutrition Examination Survey. Survivors (n=571; median age, 37.7 years and 28.5 years from cancer diagnosis) were more likely to have a preexisting CVD risk factor than the National Health and Nutrition Examination Survey (n=345; P <0.05 for all factors). While rates of CVD risk factor underdiagnosis were similar (27.1% survivors versus 26.1% National Health and Nutrition Examination Survey; P =0.73), survivors were more likely undertreated (21.0% versus 13.9%, P =0.007; odds ratio, 1.8, 95% CI, 1.2–2.7). Among survivors, the most underdiagnosed and undertreated risk factors were hypertension (18.9%) and dyslipidemia (16.3%), respectively. Men and survivors who were overweight/obese were more likely to be underdiagnosed and undertreated. Those with multiple adverse lifestyle factors were also more likely undertreated (odds ratio, 2.2, 95% CI, 1.1–4.5). Greater health‐related self‐efficacy was associated with reduced undertreatment (odds ratio, 0.5; 95% CI, 0.3–0.8). Conclusions: Greater awareness of among primary care providers and cardiologists, combined with improving self‐efficacy among survivors, may mitigate the risk of underdiagnosed and undertreated CVD risk factors among adult‐aged survivors of childhood cancer. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03104543.

15 April 2024 in Pediatric Dermatology
Verified
Journal Article
Closed access
WBWilliam Butler
William Butler
CCCasey Ruoying Cai
Casey Ruoying Cai
JCJeremi M. Carswell
Jeremi M. Carswell
JHJennifer T. Huang
Jennifer T. Huang

21 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
EIEvelyn O. Ilori
Evelyn O. Ilori
CCCasey Ruoying Cai
Casey Ruoying Cai
FSFatou Sahor
Fatou Sahor
BWBrianna Wilson
Brianna Wilson
TVTanooha Veeramachaneni
Tanooha Veeramachaneni
IHIbrahim A. Hashim
Ibrahim A. Hashim
Background: The glomerular filtration rate (GFR) is a universal clinical measure central to assessing kidney function and to the management of kidney disorders. Several formulas for the estimation of GFR are in use. The European Kidney Function Consortium (EKFC) formula has been reported to more accurately estimate the GFR as compared to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula and its recent version (REFIT equation) in European and African populations. However, validation of the EKFC equation in diverse U.S. populations, especially the Black subpopulation, is needed. Methods: Data from the electronic medical records of 75,442 individuals presenting to a large safety net county hospital with measurements of serum creatinine and/or iohexol clearance studies were used to calculate the estimated GFR (eGFR) and to determine CKD stage using the various reported eGFR formulas. The correlation between eGFR and measured GFR was determined for each equation. Results: The median eGFR for Black participants using the CKD-EPI, REFIT, and EKFC formulas was 130.6 mL/min/1.73 m2, 82.0 mL/min/1.73 m2, and 80.6 mL/min/1.73 m2 (p < 0.001), respectively. For White participants, the median eGFR using the CKD-EPI, REFIT, and EKFC formulas was 145.3 mL/min/1.73 m2, 105.6 mL/min/1.73 m2, and 99.2 mL/min/1.73 m2, respectively (p < 0.001). The REFIT equation underestimates the mGFR in Black individuals at eGFR < 80 mL/min per 1.73 m2 and in White individuals at eGFR > 20 mL/min per 1.73 m2. In comparison, the EKFC equation underestimates the mGFR at eGFR > 20 mL/min per 1.73 m2 in both Black and White individuals. The REFIT equation had the least absolute median bias as compared to EKFC and CKD-EPI in both Black and White participants (p < 0.0001). The P30 of the REFIT and EKFC equations was not statistically different for either Black or White participants (p = 0.16, p = 0.37). Conclusions: Although the accuracies (P30) of the EKFC and REFIT equations are not statistically significant (p = 0.16 and 0.37, Black and White individuals, respectively), adopting the EKFC formula in Americans requires the evaluation of each subpopulation. Both the EKFC and REFIT formulas underestimate the mGFR at a lower eGFR, which may have a direct impact on CKD classification for Black and White patients, with potentially significant implications for clinical management.